RCS - Moderna Inc - Moderna Awarded Tender for the Supply of Its mRNA

ModernaAnnouncement

24/01/2025 11:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250124:nRSX6496Ua&default-theme=true

RNS Number : 6496U  Moderna Inc  24 January 2025

Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the
European Union

The Agreement provides participating countries with the opportunity to
diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled
syringe vaccine formats

CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / January
24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been
awarded a tender for the supply of its mRNA COVID-19 vaccine in the European
Union (EU), Norway and North Macedonia. Under the resulting agreement, 17
participating countries can access Moderna's mRNA COVID-19 vaccine for up to
four years.

"This agreement presents an opportunity for Moderna to support and strengthen
national COVID-19 vaccination campaigns across participating countries," said
Chantal Friebertshäuser, Senior Vice President, General Manager - Europe
& Middle-East, Moderna. "Diversity of supply and availability of vaccine
formats such as pre-filled syringes are vital to help increase vaccination
rates and enhance vaccination campaign efficiency, ultimately strengthening
health security."

Under the agreement, Moderna can provide its COVID-19 vaccine in several
formats, including prefilled syringes. This is the preferred product
presentation for healthcare providers as it can decrease the risk of
administration errors and save time, which may ultimately improve vaccination
campaign efficiency.

In September 2024, the European Commission (EC) granted marketing
authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine
Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to
prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and
older.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the
advancement of mRNA technology, Moderna is reimagining how medicines are made
and transforming how we treat and prevent disease for everyone. By working at
the intersection of science, technology and health for more than a decade, the
company has developed medicines at unprecedented speed and efficiency,
including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and
vaccines for infectious diseases, immuno-oncology, rare diseases and
autoimmune diseases. With a unique culture and a global team driven by the
Moderna values and mindsets to responsibly change the future of human health,
Moderna strives to deliver the greatest possible impact to people through mRNA
medicines. For more information about Moderna, please visit modernatx.com and
connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and
LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended, including
statements regarding: Moderna securing an agreement in the European Union for
the supply of its mRNA COVID-19 vaccine; the opportunity and potential for up
to 17 participating countries to order COVID-19 vaccines from Moderna over a
four-year period; and healthcare provider preferences for prefilled syringes.
The forward-looking statements in this press release are neither promises nor
guarantees, and you should not place undue reliance on these forward-looking
statements because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond Moderna's control and which could
cause actual results to differ materially from those expressed or implied by
these forward-looking statements. These risks, uncertainties, and other
factors include, among others, those risks and uncertainties described under
the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the
fiscal year ended December 31, 2023 and in subsequent filings made by Moderna
with the U.S. Securities and Exchange Commission, which are available on the
SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any
intention or responsibility for updating or revising any forward-looking
statements contained in this press release in the event of new information,
future developments or otherwise. These forward-looking statements are based
on Moderna's current expectations and speak only as of the date of this press
release.

Moderna Contacts

Media:

Luke Mircea-Willats

Sr. Director, International Communications

Luke.mirceawillats@modernatx.com

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

+1 617-209-5834

Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABIMBTMTTTBIA